Quinoline derivatives as EP4 antagonists

1. A compound according to the following formula:

or a pharmaceutically acceptable salt thereof, wherein:

A is N,

B is CH;

Y and Z are CH;

Q is C;

R 1 and R 2 are independently selected from the group consisting of: C 1-6 alkoxy, C 1-6 fluoroalkoxy, C 3-6 cycloalkoxy, C 3 -6 cycloalkylmethoxy, and C 1 -6 perfluoroalkoxy;

R 3 and R 4 are independently selected from the group consisting of: H, halogen, C 1-6 alkyl, C 3 -6 cycloalkyl, C 1-6 fluoroalkyl, C 1-6 alkoxy, C 1-6 fluoroalkoxy, C 3 -6 cycloalkoxy, C 3 -6 cycloalkylmethoxy, NH 2 , —NHC 1-4 alkyl, —N(C 1-4 alkyl) 2 , NO 2 , OH and CN;

R 7 to R 10 are H;

R 11 is selected from the group consisting of: (a) C 1-6 alkyl, (b) C 3-6 cycloalkyl, (c) C 3-6 cycloalkyl substituted by one to three substituents independently selected from R 12 ; (d) aryl, (e) aryl substituted by one to three substituents independently selected from R 12 , (f) heteroaryl, (g) heteroaryl substituted by one to three substituents independently selected from R 12 , (h) heterocyclyl, (i) heterocyclyl substituted by one to three substituents independently selected from R 12 , (j) —C 1-6 alkylaryl, (k) —C 1-6 alkylaryl substituted by one to five substituents independently selected from R 12 , (k) —C 1-6 alkyl-C 3-6 cycloalkyl; (l) —C 1-6 alkyl-C 3-6 cycloalkyl substituted by one to five substituents independently selected from R 12 ; (m) —C 1-6 alkylhetereoaryl; (n) —C 1 -6 alkylheteroaryl substituted by one to five substituents independently selected from R 12 ; (o) —C 1 -6 alkylheterocyclyl; and (p) —C 1-6 alkylheterocyclyl substituted by one to five substituents independently selected from R 12 ; and fused analogs of (b) to (p); and

R 12 is selected from the group consisting of: halogen, C 1-6 alkyl, C 1-6 fluoroalkyl, C 3-6 cycloalkyl, C 1-6 alkoxy, C 1-6 fluoroalkoxy, C 3-6 cycloalkoxy, NH2, —NHC 1-4 alkyl or —N(C 1-4 alkyl) 2 , NO 2 and OH, or two R 12 groups attached to the same atom may be joined together to form a Spiro C 3 -6 cycloalkyl group.

2. A compound according to claim 1

or a pharmaceutically acceptable salt thereof, wherein:

R 11 is selected from the group consisting of: (a) —C 1-6 alkylaryl substituted by one to three substituents independently selected from R 12 , (b) —C 1-6 alkyl-C 3-6 cycloalkyl substituted by one to three substituents independently selected from R 12 ; (c) —C 1 -6 alkylheteroaryl substituted by one to three substituents independently selected from R 12 ; and (d) —C 1-6 alkylheterocyclyl substituted by one to three substituents independently selected from R 12 ; and fused analogs of (b) to (d); and

R 12 is selected from the group consisting of: halogen, C 1-6 alkyl, C 1-6 perfluoroalkyl, C 3 -6 cycloalkyl, C 1-6 alkoxy, C 1-6 perfluoroalkoxy, C 3-6 cycloalkoxy, NH2, —NHC 1-4 alkyl or —N(C 1 -4 alkyl) 2 , NO 2 and OH.

3. The compound according to claim 2 wherein R 3 is other than H.

4. The compound according to claim 1 having the following formula:

or a pharmaceutically acceptable salt thereof, wherein:

n is 0 or 1;

Ar is selected from the group consisting of: C 3-6 cycloalkyl, aryl, heteroaryl and heterocyclyl, or a fused analog of C 3-6 cycloalkyl, aryl, heteroaryl and heterocyclyl;

R A and R B are independently selected from the group consisting of C 1-4 alkoxy, C 1-4 perfluoroalkoxy, C 3-6 cycloalkoxy and C 3-6 cycloalkylmethoxy;

R C and R D are joined together to form carbonyl and R E and R F are hydrogen;

R G is selected from the group consisting of: F, Cl, Br, I, methyl, ethyl, methoxy, CF 3 , CF 3 O— and CN;

R H and R I are independently hydrogen or methyl; or R H and R I may be joined together to form a C 3-6 cycloalkyl ring; and

each X 2 and X 3 is independently selected from the group consisting of: F, Cl, Br, I, methyl, ethyl, methoxy, CF 3 , CF 3 O— and OH.

5. The compound according to claim 4 wherein n is 1 and Ar is selected from the group consisting of phenyl, naphthyl and pyridyl; or n is 0 and Ar is selected from the group consisting of: indanyl and tetrahydronaphthyl.

6. The compound according to claim 5 wherein n is 1 and Ar is phenyl.

7. The compound according to claim 6 wherein at least one X 3 is present and is attached at the 2-position on the phenyl ring.

8. The compound according to claim 6 wherein X 3 is methoxy.

9. The compound according to claim 1 selected from the group consisting of:

(1) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide;

(2) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)benzyl]sulfonyl}-2-phenylacetamide;

(3)N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-phenylacetamide;

(4) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-phenylpropanamide;

(5) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl }-2[2-(trifluoromethyl)phenyl]acetamide;

(6) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-fluorophenyl)acetamide;

(7) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-pyridin-4-ylacetamide;

(8) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-pyridin-3-ylacetamide;

(9) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3 -methylbenzyl]sulfonyl}-2-pyridin-2-ylacetamide;

(10) 2-(2-chlorophenyl)-N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}acetamide;

(11) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-1-phenylcyclopropanecarboxamide;

(12) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3 -methylbenzyl]sulfonyl}-[2-(trifluoromethoxy)phenyl]acetamide;

(13) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2,5-dimethoxyphenyl)acetamide;

(14) 2-(5-bromo-2-methoxyphenyl)-N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3 -methylbenzyl]sulfonyl}acetamide;

(15) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3 -methylbenzyl]sulfonyl}-2-(1-naphthyl)acetamide;

(16) N-{[4-(5,9-diethoxy-8-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)benzyl]sulfonyl}-2-phenylacetamide;

(17) N-{[4-(5,9-diethoxy-8-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3 -methylbenzyl]sulfonyl}-2-phenylacetamide;

(18) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3 -methylbenzyl]sulfonyl}-1-(2-methoxyphenyl)cyclopropanecarboxamide;

(19) N-{[4-(5,9-diisopropoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3 -methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide;

(20) 2-(2-methoxyphenyl)-N-({3-methyl-4[6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]benzyl }sulfonyl)propanamide;

(21) N-({4-[5,9-bis(cyclopropyloxy)-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]-3 -methylbenzyl }sulfonyl)-2-(2-methoxyphenyl)acetamide;

(22) N-{[3-bromo-4-(5,9-diethoxy-6-oxo-6,8-dihydro -7H-pyrrolo[3,4-g]quinolin-7-yl)benzyl]sulfonyl}-2-methyl-2-(1-naphthyl)propanamide;

(23) N-{[4-(5-ethoxy-9-isopropoxy-6-oxo-6,8-dihydro -7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-pyridin-2-ylpropanamide;

(24) N-({3-methyl-4-[6-oxo-5,9-bis(trifluoromethoxy)-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]benzyl}sulfonyl)-2-pyridin-2-ylacetamide; and

(25) N-({4-[5,9-bis(difluoromethoxy)-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]-3 -methylbenzyl}sulfonyl)-2-(2-chloro-5-fluorophenyl)-2-methylpropanamide;

or a pharmaceutically acceptable salt of any of the above.

10. A pharmaceutical composition comprising a compound according to claim 1 in admixture with one or more physiologically acceptable carriers or excipients.

11. A compound according to claim 1 having the following formula:

or a pharmaceutically acceptable salt thereof, wherein:

n is 0 or 1;

Ar is selected from the group consisting of: C 3-6 cycloalkyl, aryl, heteroaryl and heterocyclyl, or a fused analog of C 3-6 cycloalkyl, aryl, heteroaryl and heterocyclyl;

R A and R B are the same and selected from the group consisting of: ethoxy, 2,2,2-trifluoroethoxy and isopropoxy;

R G is selected from the group consisting of: Cl, Br and methyl;

R H and R I are independently selected from the group consisting of: hydrogen, halogen, methyl and methoxy; or R H and R I may be joined together to form a cyclopropyl ring; and

X 3 is selected from the group consisting of: halogen, C 1-4 alkyl; C 1 -4 fluoroalkyl, C 1-4 alkoxy, C 1-4 fluoroalkoxy and OH.

12. The compound according to claim 11 , wherein:

R A and R B are both 2,2,2-trifluoroethoxy; and

R G is methyl.

13. The compound according to claim 12 , wherein:

n is 1; and

R H and R I are joined together to form a cyclopropyl ring.

14. The compound according to claim 13 wherein Ar is phenyl.

15. A compound according to claim 1 selected from the following group:

(1) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3 -methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)propanamide;

(2) 2-(2,6-dichlorophenyl)-N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}acetamide;

(3) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}indane-1-carboxamide;

(4) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo [3,4-g]quinolin-7-yl)-3 -methylbenzyl]sulfonyl}-1,2,3,4-tetrahydronaphthalene-1-carboxamide;

(5) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo [3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-mesitylacetamide;

(6) 1-(2,4-dichlorophenyl)-N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-]quinolin-7-yl1)-3 -methylbenzyl]sulfonyl}cyclopropanecarboxamide;

(7) (2R)-N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-methoxy-2-phenylacetamide;

(8) (2S)-N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-methoxy-2-phenylacetamide;

(9) 2-(2-methoxyphenyl)-N-({3-methyl-4-[6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro -7H-pyrrolo[3,4-g]quinolin-7-yl]benzyl}sulfonyl)acetamide;

(10) N-({3-methyl-4-[6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]benzyl}sulfonyl)-2-pyridin-2-ylacetamide;

(11) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(3 -methoxypyridin-2-yl)acetamide;

(12) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl }-2-pyridin-2-ylpropanamide;

(13) N-({3-methyl-4-[6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]benzyl}sulfonyl)-2-pyridin-2-ylpropanamide;

(14) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-ethoxyphenyl)acetamide;

(15) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3 -methylbenzyl]sulfonyl}-2,2-difluoro-2-phenylacetamide;

(16) N-{[4-(5,9-diisopropoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-1-(2-methoxyphenyl)cyclopropanecarboxamide;

(17) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2,6-dimethoxyphenyl)acetamide;

(18) 1-(2-methoxyphenyl)-N-({3-methyl-4-[6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro -7H-pyrrolo[3,4-g]quinolin-7-yl]benzyl}sulfonyl)cyclopropanecarboxamide;

(19) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-[2-(difluoromethoxy)phenyl]acetamide;

(20) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3 -methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)-N-methylacetamide;

(21) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3 -methylbenzyl]sulfonyl}bicyclo[4.2.0]octa-1,3,5-triene-7-carboxamide;

(22) N-{[4-(5,9-dimethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3 -methylbenzyl]sulfonyl}-1-(2-methoxyphenyl)cyclopropanecarboxamide;

(23) 2-(2-methoxyphenyl)-N-methyl-N-({3-methyl-4-[6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]benzyl}sulfonyl)acetamide;

(24) 1-(2,6-dichlorophenyl)-N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}cyclopropanecarboxamide;

(25) N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H -pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-1-(2,6-dimethoxyphenyl)cyclopropanecarboxamide;

(26) 1-(2,6-dichlorophenyl)-N-({3-methyl-4- [6-oxo -5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]benzyl }sulfonyl)cyclopropanecarboxamide;

(27) N-{[3 -bromo-4-(5,9-diethoxy-6-oxo-6,8-dihydro -7H-pyrrolo[3,4-g]quinolin-7-yl)benzyl]sulfonyl}-1-(2-methoxyphenyl)cyclopropanecarboxamide;

(28) 1-(2,6-dimethoxyphenyl)-N-({3-methyl-4-[6-oxo -5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]benzyl}sulfonyl)cyclopropanecarboxamide;

(29) N-({3-chloro-4-6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]benzyl}sulfonyl)-1-(2,6-dimethoxyphenyl)cyclopropanecarboxamide;

(30) N-({3 -chloro-4-[6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]benzyl}sulfonyl)-1-(2-methoxyphenyl)cyclopropanecarboxamide;

(31) 1-(2-chloro-6-fluorophenyl)-N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}cyclopropanecarboxamide;

(32) 1-(3-bromo-2,6-dimethoxyphenyl)-N-({3 -methyl-4-[6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]benzyl}sulfonyl)cyclopropanecarboxamide;

(33) N-({4- [3-bromo-6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]-3 -methylbenzyl}sulfonyl)-1-(2,6-dimethoxyphenyl)cyclopropanecarboxamide;

(34) 1-(2,6-diethylphenyl)-N-({3-methyl-4-[6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]benzyl}sulfonyl)cyclopropanecarboxamide;

(35) 2-(2,6-difluorophenyl)-N-({3-methyl-4-[6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]benzyl}sulfonyl)acetamide;

(36) 2-(2-bromophenyl)-N-({3-methyl-4-[6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro -7H-pyrrolo[3,4-g]quinolin-7-yl]benzyl}sulfonyl)acetamide;

(37) N-({3-methyl-4-[6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]benzyl}sulfonyl)-2-(2-methylphenyl)acetamide;

(38) 2-(5 -bromo-2-methoxyphenyl)-N-({3 -methyl-4-[6-oxo-5,9-bis(2,2,2-trifluoroethoxy) -6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]benzyl}sulfonyl)acetamide;

(39) 2-(2,5-dimethoxyphenyl)-N-({3 -methyl-4-[6-oxo -5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-]benzyl}sulfonyl)acetamide;

(40) 1-(2,6-dimethylphenyl)-N-({3-methyl-4-[6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]benzyl}sulfonyl)cyclopropanecarboxamide;

(41) 2-(2,3-dimethoxyphenyl)-N-({3-methyl-4-[6-oxo -5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]benzyl}sulfonyl)acetamide;

(42) 2-(2,6-dimethoxyphenyl)-N-({3-methyl-4-[6-oxo -5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]benzyl}sulfonyl)-2-oxoacetamide;

(43) 1-(3-hydroxy-2,6-dimethoxyphenyl)-N-({3-methyl-4-[6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro-7H-pyrrolo[4-g]quinolin-7-yl]benzyl}sulfonyl)cyclopropanecarboxamide;

(44) 1-(5-bromo-2-methoxyphenyl)-N-({3-methyl-4-[6-oxo-5,9-bis(2,2,2-trifluoroethoxy) -6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]benzyl}sulfonyl)cyclopropanecarboxamide;

(45) 2-(2,6-dimethoxyphenyl)-2-methoxy-N-({3-methyl-4-[6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]benzyl}sulfonyl)acetamide; and

(46) 2-(2,3-dichlorophenyl)-N-({3-methyl-4-[6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]benzyl}sulfonyl)acetamide;

or a pharmaceutically acceptable salt of any of the aforementioned.

16. The compound according to claim 1 having the formula:

or a pharmaceutically acceptable salt thereof, wherein:

n is 0 or 1;

Ar is selected from the group consisting of: C 3-6 cycloalkyl, aryl, heteroaryl and heterocyclyl, or a fused analog of C 3-6 cycloalkyl, aryl, heteroaryl and heterocyclyl;

R A and R B are independently selected from the group consisting of C 1-4 alkoxy, C 1-4 fluoroalkoxy, C 3-6 cycloalkoxy and C 3-6 cycloalkylmethoxy;

R C and R D are hydrogen and R E and R F are joined together to form carbonyl;

R G is selected from the group consisting of: F, Cl, Br, I, methyl, ethyl, methoxy, CF 3 , CF 3 O— and CN;

R H and R I are independently hydrogen or methyl; or R H and R I may be joined together to form a C 3-6 cycloalkyl ring; and

each X 2 and X 3 is independently selected from the group consisting of: F, Cl, Br, I, methyl, ethyl, methoxy, CF 3 , CF 3 O— and OH.

17. A compound having the formula:

or a pharmaceutically acceptable salt thereof.